2916399090 Other aromatic monocarboxylic acids. VAT:17.0% Tax refund rate:9.0% Regulatory conditions:nothing MFN tariff:6.5% general tariff:30.0%
Product Name, component content, use to, Acrylic acid\Acrylates or esters shall be packaged clearly
2916399090 other aromatic monocarboxylic acids, their anhydrides, halides, peroxides, peroxyacids and their derivatives VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0%
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | D491835-1g |
2,2-Diphenylpentanoic Acid |
841-32-7 | 1g |
$ 141.00 | 2023-09-07 | ||
| TRC | D491835-2g |
2,2-Diphenylpentanoic Acid |
841-32-7 | 2g |
$219.00 | 2023-05-18 | ||
| TRC | D491835-5g |
2,2-Diphenylpentanoic Acid |
841-32-7 | 5g |
$523.00 | 2023-05-18 | ||
| TRC | D491835-10g |
2,2-Diphenylpentanoic Acid |
841-32-7 | 10g |
$1034.00 | 2023-05-18 | ||
| TRC | D491835-25g |
2,2-Diphenylpentanoic Acid |
841-32-7 | 25g |
$1504.00 | 2023-05-18 | ||
| abcr | AB415136-500 mg |
2,2-Diphenylpentanoic acid |
841-32-7 | 500MG |
€195.40 | 2023-02-03 | ||
| abcr | AB415136-1 g |
2,2-Diphenylpentanoic acid |
841-32-7 | 1g |
€239.00 | 2023-04-24 | ||
| abcr | AB415136-5 g |
2,2-Diphenylpentanoic acid |
841-32-7 | 5g |
€656.50 | 2023-04-24 | ||
| abcr | AB415136-10 g |
2,2-Diphenylpentanoic acid |
841-32-7 | 10g |
€1074.00 | 2023-04-24 | ||
| eNovation Chemicals LLC | D770212-5g |
Benzeneacetic acid, a-phenyl-a-propyl- |
841-32-7 | 98% | 5g |
$340 | 2023-09-02 |
Audited Supplier
2,2-Diphenylpentanoic Acid (CAS: 841-32-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This compound, characterized by its diphenyl moiety and pentanoic acid backbone, has been the subject of several studies exploring its biological activity, mechanism of action, and potential as a lead compound in drug development. Recent literature highlights its role in modulating key biological pathways, making it a promising candidate for further investigation.
A 2023 study published in the Journal of Medicinal Chemistry investigated the inhibitory effects of 2,2-Diphenylpentanoic Acid on inflammatory cytokines, demonstrating its potential as an anti-inflammatory agent. The researchers utilized in vitro assays and molecular docking simulations to elucidate its interaction with cyclooxygenase-2 (COX-2), a key enzyme in the inflammatory response. The results indicated a significant reduction in pro-inflammatory cytokine levels, suggesting its applicability in treating chronic inflammatory diseases.
In addition to its anti-inflammatory properties, recent research has explored the compound's potential in oncology. A 2024 study in Bioorganic & Medicinal Chemistry Letters reported that 2,2-Diphenylpentanoic Acid exhibits selective cytotoxicity against certain cancer cell lines, particularly those associated with breast and prostate cancers. The study employed high-throughput screening and transcriptomic analysis to identify the compound's impact on apoptosis-related genes, revealing its ability to induce programmed cell death in malignant cells while sparing normal tissues.
The synthesis and optimization of 2,2-Diphenylpentanoic Acid derivatives have also been a focus of recent investigations. A team of researchers from the University of Cambridge published a paper in Chemical Communications (2024) detailing a novel synthetic route that improves yield and purity while reducing environmental impact. Their work highlights the importance of green chemistry principles in the development of pharmaceutical intermediates, with 2,2-Diphenylpentanoic Acid serving as a model compound for these advancements.
Pharmacokinetic studies of 2,2-Diphenylpentanoic Acid have provided valuable insights into its drug-like properties. Research conducted at the National Institutes of Health (2023) demonstrated favorable absorption and distribution characteristics in animal models, with particular attention to its blood-brain barrier permeability. These findings open new possibilities for the compound's application in central nervous system disorders, though further optimization may be required to enhance its metabolic stability.
As the scientific community continues to explore the potential of 2,2-Diphenylpentanoic Acid, interdisciplinary collaborations between chemists, biologists, and pharmacologists are proving crucial. The compound's versatility and demonstrated biological activities position it as a valuable tool for both basic research and drug discovery efforts. Future studies are expected to focus on structure-activity relationship optimization and clinical translation of these promising preclinical findings.
